ArticleFrontiers in immunology2025
Circulating SARS-CoV-2 spike IgG antibody responses in cancer patients following multiple COVID-19 vaccination boosters.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Article
- Cancer and COVID-19: A review of immune insights and partnerships to inform public health strategy.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2026Review
- Neutralizing antibody responses to the primary series of a COVID-19 mRNA vaccine in the cancer cohort under active treatment.Human vaccines & immunotherapeutics · 2025Article
- Humoral immune responses to the second dose of a COVID-19 mRNA vaccine in cancer patients undergoing treatment.Human vaccines & immunotherapeutics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Individuals with cancer have a higher risk of SARS-CoV-2 infection, severe disease, hospitalization and death compared to healthy individuals. Understanding the immune response to different doses of COVID-19 vaccines in this population is essential to inform vaccine recommendations. This study aimed to compare the post-vaccination humoral immune response of people with cancer versus healthy participants via assessment of anti-spike IgG antibody levels and avidity 1 month and 6 months post-last vaccination. Methods: Circulating anti-spike IgG levels and antibody avidity were measured in sera from cancer and healthy cohorts using ELISA and chaotropic-based avidity assays. Results: In general, individuals with hematological cancers showed significantly lower antibody levels and avidity across two-, three- and four-doses compared to healthy individuals. Additionally, individuals with hematological cancers who received two doses of vaccine exhibited a significantly slower avidity development at both time points compared to healthy individuals. In contrast, individuals with solid cancers exhibited similar antibody levels and avidity compared to healthy participants. Factors including age, sex and vaccine received also influenced immune responses. Discussion: These findings suggest the need for customized vaccination strategies for vulnerable populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.